Phase 1 Trial of BC2059 (Tegavivint) in Patients With Unresectable Desmoid Tumor
Phase of Trial: Phase I
Latest Information Update: 18 Feb 2019
Price : $35 *
At a glance
- Drugs Tegatrabetan (Primary)
- Indications Fibroma
- Focus Adverse reactions; First in man
- Sponsors Iterion Therapeutics
- 05 Dec 2018 According to an Iterion Therapeutics media release, the trial is being funded with proceeds from Sante Ventures that included GOOSE Society and AngelMD and a grant from the Cancer Prevention Research Institute of Texas (CPRIT).
- 24 Jul 2018 Status changed from not yet recruiting to recruiting.
- 12 Mar 2018 New trial record